INVESTMENTS THAT MATTER

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.

OUR PROVEN STRATEGY

At Agent Capital, we proactively guide biotech companies to milestones and exits.

With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward – no matter the stage or investment type.

TYPICALLY, OUR KEY INVESTMENT AREAS OF FOCUS INCLUDE:

Rare Diseases
Oncology
Neurology
Immunology
Learn More

Featured Portfolio Company

Dice Therapeutics

ViTToria Biotherapeutics

Dragonfly Therapeutics

Carisma Therapeutics

Skyhawk Therapeutics

Flare Therapeutics

ImCheck Therapeutics

Orchard Therapeutics

Pliant Therapeutics

Entrada Therapeutics

Zenas Biopharma

Star Therapeutics

Pyxis Oncology

Precision Biosciences

Palvella Therapeutics

View Full Portfolio

Featured News

Press Release | December 7, 2023

Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

Read More

Press Release | December 5, 2023

Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors

Read More

Press Release | November 28, 2023

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

Read More

View All